French health insurance cuts reimbursement for low-efficacy drugs
Starting in 2027, drugs like Spasfon and Gaviscon will only be reimbursed at 5% by France’s public health insurance.
Published 3h1 sourceImportant
Lire en français
≈ 22s
The fact
The measure aims to cut public spending, but supplemental insurers may not cover the difference.
Patients will bear a larger share of the cost for these treatments.
Click the link to read an article on the topic: